Ethos Technologies
$11.87
256
+$0.74+6.65% Thursday 20:00
Statistics
Day High
12
Day Low
10.87
52W High
19
52W Low
9.45
Volume
279,212
Avg. Volume
617,043
Mkt Cap
1.16B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
13MayExpected
Expected EPS
-0.11371368750000001
Actual EPS
N/A
Financials
-27,243.83%Profit Margin
Unprofitable470,000Revenue
-128.05MNet Income
Analyst Ratings
$17.78Average Price Target
The highest estimate is 33.00.
From 10 ratings within the last 6 months. This is not an investment recommendation.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy 80%
Hold 20%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow LIFE. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
AMGEN
AMGN
Mkt Cap160.66B
Gilead Sciences
GILD
Mkt Cap148.78B
Biogen
BIIB
Mkt Cap22.63B
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Abbvie
ABBV
Mkt Cap385.18B
Novartis
NVS
Mkt Cap237.61B
Pfizer
PFE
Mkt Cap140.15B
Merck
MRK
Mkt Cap214.76B
Astrazeneca
AZN
Mkt Cap256.58B
About
Health Technology
Biotechnology
Manufacturing
Biological Product (except Diagnostic) Manufacturing
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
Show more...
CEO
Sanjay Shukla
Employees
56
Country
US
ISIN
US29765A1016
Listings
0 Comments
Share your thoughts
FAQ
What is Ethos Technologies stock price today?▼
The current price of LIFE is $11.87 USD — it has increased by +6.65% in the past 24 hours. Watch Ethos Technologies stock price performance more closely on the chart.
What is Ethos Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Ethos Technologies stocks are traded under the ticker LIFE.
What is Ethos Technologies market cap?▼
Today Ethos Technologies has the market capitalization of 1.16B
When is the next Ethos Technologies earnings date?▼
Ethos Technologies is going to release the next earnings report on May 13, 2026.
What were Ethos Technologies earnings last quarter?▼
LIFE earnings for the last quarter are -0.14 USD per share, whereas the estimation was -0.18 USD resulting in a +23.81% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ethos Technologies revenue for the last year?▼
Ethos Technologies revenue for the last year amounts to 470,000 USD.
What is Ethos Technologies net income for the last year?▼
LIFE net income for the last year is -128.05M USD.
How many employees does Ethos Technologies have?▼
As of April 03, 2026, the company has 56 employees.
In which sector is Ethos Technologies located?▼
Ethos Technologies operates in the Professional, Scientific, and Technical Services sector.
When did Ethos Technologies complete a stock split?▼
The last stock split for Ethos Technologies was on July 01, 2019 with a ratio of 1:14.
Where is Ethos Technologies headquartered?▼
Ethos Technologies is headquartered in San Diego, US.